Terms: = Lung cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889 AND Treatment
15 results:
1. DNA repair and immune checkpoint blockade response.
Guo JA; Alshalalfa M; Kim DY; Hoffman HI; Shiau C; Su J; Hwang WL; Mahal BA
Cancer Genet; 2022 Jun; 264-265():1-4. PubMed ID: 35245846
[TBL] [Abstract] [Full Text] [Related]
2. Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell lines.
Suzuki T; Sirimangkalakitti N; Baba A; Toyoshima-Nagasaki R; Enomoto Y; Saito N; Ogasawara Y
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35147203
[TBL] [Abstract] [Full Text] [Related]
3. Contribution of XPD and xpf Polymorphisms to Susceptibility of Non-Small Cell lung cancer in High-Altitude Areas.
Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Li G
Public Health Genomics; 2021; 24(3-4):189-198. PubMed ID: 33827099
[TBL] [Abstract] [Full Text] [Related]
4. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
[TBL] [Abstract] [Full Text] [Related]
5. Nanoparticle-Mediated Gene Silencing for Sensitization of lung cancer to Cisplatin Therapy.
Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
[TBL] [Abstract] [Full Text] [Related]
6. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract] [Full Text] [Related]
7. Effect of Reasons for Screen Failure on Subsequent treatment Outcomes in cancer Patients Assessed for Clinical Trials.
Tiu C; Loh Z; Gan CL; Gan H; John T; Hawkes E
Oncology; 2019; 97(5):270-276. PubMed ID: 31266008
[TBL] [Abstract] [Full Text] [Related]
8. Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in lung cancer.
Heyza JR; Lei W; Watza D; Zhang H; Chen W; Back JB; Schwartz AG; Bepler G; Patrick SM
Clin Cancer Res; 2019 Apr; 25(8):2523-2536. PubMed ID: 30538112
[TBL] [Abstract] [Full Text] [Related]
9. An ercc4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
Zhang R; Jia M; Xu Y; Qian D; Wang M; Zhu M; Sun M; Chang J; Wei Q
Int J Cancer; 2018 Mar; 142(6):1218-1229. PubMed ID: 29134637
[TBL] [Abstract] [Full Text] [Related]
10. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell lung cancer: ERCC1 Trial (ET).
Lee SM; Falzon M; Blackhall F; Spicer J; Nicolson M; Chaudhuri A; Middleton G; Ahmed S; Hicks J; Crosse B; Napier M; Singer JM; Ferry D; Lewanski C; Forster M; Rolls SA; Capitanio A; Rudd R; Iles N; Ngai Y; Gandy M; Lillywhite R; Hackshaw A
J Clin Oncol; 2017 Feb; 35(4):402-411. PubMed ID: 27893326
[TBL] [Abstract] [Full Text] [Related]
11. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
[TBL] [Abstract] [Full Text] [Related]
12. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer.
Huang SJ; Wang YF; Jin ZY; Sun JY; Guo ZL
Tumour Biol; 2014 May; 35(5):4023-9. PubMed ID: 24370899
[TBL] [Abstract] [Full Text] [Related]
13. Immunodetection of DNA repair endonuclease ERCC1-xpf in human tissue.
Bhagwat NR; Roginskaya VY; Acquafondata MB; Dhir R; Wood RD; Niedernhofer LJ
Cancer Res; 2009 Sep; 69(17):6831-8. PubMed ID: 19723666
[TBL] [Abstract] [Full Text] [Related]
14. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract] [Full Text] [Related]
15. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.
Kovacs MS; Hocking DJ; Evans JW; Siim BG; Wouters BG; Brown JM
Br J Cancer; 1999 Jun; 80(8):1245-51. PubMed ID: 10376978
[TBL] [Abstract] [Full Text] [Related]
